Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trialDaniel V.T. Catenacci, Yung‐Jue Bang, Haeseong Park et al.|The Lancet Oncology|2020Cited by 190
Imaging Biomarkers in ImmunotherapyRosalyn A. Juergens, Karen Y. Gulenchyn, Katherine Zukotynski et al.|Biomarkers in Cancer|2016Cited by 47
Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrenceNiki Esfahanian, Geoffrey Liu, Sze Wah Samuel Chan et al.|Cancer Treatment and Research Communications|2023Cited by 2